BridgeBio Pharma (NASDAQ:BBIO) CEO Sells $2,877,600.00 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar sold 40,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $71.94, for a total value of $2,877,600.00. Following the sale, the chief executive officer owned 695,686 shares of the company’s stock, valued at approximately $50,047,650.84. This trade represents a 5.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Neil Kumar also recently made the following trade(s):

• On Thursday, January 8th, Neil Kumar sold 40,000 shares of BridgeBio Pharma stock. The stock was sold at an average price of $73.97, for a total value of $2,958,800.00.
• On Monday, December 15th, Neil Kumar sold 30,011 shares of BridgeBio Pharma stock. The shares were sold at an average price of $74.64, for a total value of $2,240,021.04.
• On Thursday, December 4th, Neil Kumar sold 40,000 shares of BridgeBio Pharma stock. The shares were sold at an average price of $74.40, for a total value of $2,976,000.00.
• On Thursday, November 20th, Neil Kumar sold 26,156 shares of BridgeBio Pharma stock. The shares were sold at an average price of $65.84, for a total transaction of $1,722,111.04.

BridgeBio Pharma Price Performance

BBIO traded up $2.73 during midday trading on Thursday, reaching $76.06. 9,160,897 shares of the company’s stock were exchanged, compared to its average volume of 3,288,562. BridgeBio Pharma, Inc. has a 1-year low of $28.33 and a 1-year high of $84.94. The stock has a market capitalization of $14.66 billion, a PE ratio of -18.20 and a beta of 1.13. The business’s 50-day moving average price is $75.54 and its 200 day moving average price is $62.79.

Key Stories Impacting BridgeBio Pharma

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: PROPEL 3 met its primary endpoint (AHV) with strong statistical significance (p<0.0001); mean treatment difference vs. placebo ~+2.10 cm/yr (LS mean +1.74 cm/yr). The study also showed significant improvements in height Z‑score and the first statistically significant improvement in body proportionality for children <8 — supportive efficacy and a clear regulatory story. BridgeBio press release
• Positive Sentiment: Analyst and media reaction highlighted the data as “compelling,” helping lift the stock and reinforcing investor confidence that BridgeBio can pursue NDA/MAA submissions in H2 2026 — a clear near‑term value catalyst. ProactiveInvestors article
• Neutral Sentiment: Major news outlets and trade press picked up the trial top‑line, amplifying market attention and trading volume; coverage notes the potential market impact but also the usual regulatory and commercialization risks ahead. Reuters coverage
• Neutral Sentiment: Market commentary and aggregated reports (Seeking Alpha / MSN) noted the rally and provided context on the trial readout; these summaries help volume and sentiment but don’t add new clinical detail. Seeking Alpha article
• Negative Sentiment: Near‑term headwind: analysts/publications flag that BridgeBio may still report negative quarterly earnings, which can pressure the stock around the upcoming results and offset some enthusiasm from the trial readout. Zacks earnings preview
• Negative Sentiment: Corporate governance signal: recent reporting highlights substantial insider selling activity over prior periods, which some investors view as a potential governance/lock‑up or timing concern and could weigh on sentiment despite the positive data. QuiverQuant summary

Analysts Set New Price Targets

Several equities analysts have weighed in on BBIO shares. Wells Fargo & Company lifted their target price on BridgeBio Pharma from $84.00 to $88.00 and gave the company an “overweight” rating in a research note on Tuesday, January 20th. Leerink Partners increased their price target on BridgeBio Pharma from $75.00 to $86.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. Truist Financial increased their price target on BridgeBio Pharma from $80.00 to $86.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. HC Wainwright reiterated a “buy” rating and set a $90.00 price target on shares of BridgeBio Pharma in a report on Monday, November 3rd. Finally, The Goldman Sachs Group upped their target price on BridgeBio Pharma from $55.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Twenty-two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $79.95.

Institutional Trading of BridgeBio Pharma

A number of hedge funds have recently bought and sold shares of the company. Cibc World Markets Corp bought a new position in BridgeBio Pharma during the 4th quarter worth approximately $803,000. Commonwealth Equity Services LLC boosted its position in shares of BridgeBio Pharma by 4.9% during the fourth quarter. Commonwealth Equity Services LLC now owns 5,179 shares of the company’s stock valued at $396,000 after buying an additional 244 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of BridgeBio Pharma by 460.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 382,569 shares of the company’s stock worth $29,252,000 after buying an additional 314,316 shares during the last quarter. Federated Hermes Inc. increased its stake in shares of BridgeBio Pharma by 38.2% in the 4th quarter. Federated Hermes Inc. now owns 586,795 shares of the company’s stock worth $44,884,000 after purchasing an additional 162,100 shares in the last quarter. Finally, Skandinaviska Enskilda Banken AB publ raised its stake in BridgeBio Pharma by 59.7% during the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 237,791 shares of the company’s stock worth $18,189,000 after acquiring an additional 88,874 shares during the period. Institutional investors own 99.85% of the company’s stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.